BIOS Fund I QP, LP insider trades: Actuate Therapeutics (ACTU) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where BIOS Fund I QP, LP reports to the SEC
Open-market buys and sales
50 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Jun 27, 2025 | ACTU | ↑ Buy | 71,428 | $7.00 | $500K | Directly held by Bios 2024 Co-Invest, LP | Jun 30, 2025 (3d) |
| Jun 13, 2025 | LTRN | ↓ Sell | 14,218 | $3.09 | $44K | By Bios Fund II QP, LP | Jun 13, 2025 (0d) |
| Jun 13, 2025 | LTRN | ↓ Sell | 12,319 | $3.09 | $38K | By Bios Fund I, LP | Jun 13, 2025 (0d) |
| Jun 13, 2025 | LTRN | ↓ Sell | 7,206 | $3.09 | $22K | By Bios Fund I QP, LP | Jun 13, 2025 (0d) |
| Jun 13, 2025 | LTRN | ↓ Sell | 4,354 | $3.09 | $13K | by Bios Fund II, LP | Jun 13, 2025 (0d) |
| Jun 13, 2025 | LTRN | ↓ Sell | 1,903 | $3.09 | $6K | By Bios Fund II NT, LP | Jun 13, 2025 (0d) |
| Jun 12, 2025 | LTRN | ↓ Sell | 21,900 | $3.38 | $74K | By Bios Fund II QP, LP | Jun 13, 2025 (1d) |
| Jun 12, 2025 | LTRN | ↓ Sell | 18,976 | $3.38 | $64K | By Bios Fund I, LP | Jun 13, 2025 (1d) |
| Jun 12, 2025 | LTRN | ↓ Sell | 11,099 | $3.38 | $38K | By Bios Fund I QP, LP | Jun 13, 2025 (1d) |
| Jun 12, 2025 | LTRN | ↓ Sell | 6,706 | $3.38 | $23K | By Bios Fund II, LP | Jun 13, 2025 (1d) |
| Jun 12, 2025 | LTRN | ↓ Sell | 2,932 | $3.38 | $10K | By Bios Fund II NT, LP | Jun 13, 2025 (1d) |
| May 29, 2025 | LTRN | ↓ Sell | 19,990 | $2.99 | $60K | By Bios Fund II QP, LP | May 29, 2025 (0d) |
| May 29, 2025 | LTRN | ↓ Sell | 17,320 | $2.99 | $52K | By Bios Fund I, LP | May 29, 2025 (0d) |
| May 29, 2025 | LTRN | ↓ Sell | 10,131 | $2.99 | $30K | By Bios Fund I QP, LP | May 29, 2025 (0d) |
| May 29, 2025 | LTRN | ↓ Sell | 6,121 | $2.99 | $18K | By Bios Fund II, LP | May 29, 2025 (0d) |
| May 29, 2025 | LTRN | ↓ Sell | 2,675 | $2.99 | $8K | By Bios Fund II NT, LP | May 29, 2025 (0d) |
| Aug 14, 2024 | ACTU | ↑ Buy | 375,000 | $8.00 | $3.0M | Directly held by Bios Clinical Opportuni | Aug 14, 2024 (0d) |
| Aug 14, 2024 | ACTU | ↑ Buy | 125,000 | $8.00 | $1.0M | Directly held by Bios 2024 Co-Invest, LP | Aug 14, 2024 (0d) |
| Aug 14, 2024 | ACTU | ↓ Sell | 17,361 | $9.00 | $156K | Directly held by Bios Fund II QP, LP | Aug 14, 2024 (0d) |
| Aug 14, 2024 | ACTU | ↓ Sell | 5,314 | $9.00 | $48K | Directly held by Bios Fund II, LP | Aug 14, 2024 (0d) |
| Aug 14, 2024 | ACTU | ↓ Sell | 2,324 | $9.00 | $21K | Directly held by Bios Fund II NT, LP | Aug 14, 2024 (0d) |
| May 24, 2024 | LTRN | ↓ Sell | 20,832 | $6.30 | $131K | By Bios Fund II QP, LP | May 28, 2024 (4d) |
| May 24, 2024 | LTRN | ↓ Sell | 6,379 | $6.30 | $40K | By Bios Fund II, LP | May 28, 2024 (4d) |
| May 24, 2024 | LTRN | ↓ Sell | 2,789 | $6.30 | $18K | By Bios Fund II NT, LP | May 28, 2024 (4d) |
| Feb 29, 2024 | LTRN | ↓ Sell | 100,025 | $4.70 | $470K | By Bios Fund II QP, LP | Feb 29, 2024 (0d) |
| Feb 29, 2024 | LTRN | ↓ Sell | 30,585 | $4.70 | $144K | By Bios Fund II, LP | Feb 29, 2024 (0d) |
| Feb 29, 2024 | LTRN | ↓ Sell | 13,390 | $4.70 | $63K | By Bios Fund II NT, LP | Feb 29, 2024 (0d) |
| Jan 17, 2024 | LTRN | ↓ Sell | 40,893 | $4.20 | $172K | By Bios Fund II QP, LP | Jan 19, 2024 (2d) |
| Jan 17, 2024 | LTRN | ↓ Sell | 12,521 | $4.20 | $53K | By Bios Fund II, LP | Jan 19, 2024 (2d) |
| Jan 17, 2024 | LTRN | ↓ Sell | 5,475 | $4.20 | $23K | By Bios Fund II NT, LP | Jan 19, 2024 (2d) |
| Nov 29, 2023 | LTRN | ↓ Sell | 91,708 | $3.44 | $315K | By Bios Fund I, LP | Dec 1, 2023 (2d) |
| Nov 29, 2023 | LTRN | ↓ Sell | 53,640 | $3.44 | $185K | By Bios Fund I QP, LP | Dec 1, 2023 (2d) |
| Jun 21, 2023 | AZTR | ↑ Buy | 456,412 | $5.00 | $2.3M | Directly held by Bios Fund III QP, LP | Jun 23, 2023 (2d) |
| Jun 21, 2023 | AZTR | ↑ Buy | 73,708 | $5.00 | $369K | Directly held by Bios Fund III NT, LP | Jun 23, 2023 (2d) |
| Jun 21, 2023 | AZTR | ↑ Buy | 69,880 | $5.00 | $349K | Directly held by Bios Fund III, LP | Jun 23, 2023 (2d) |
| Nov 28, 2022 | CGTX | ↑ Buy | 12,220 | $2.65 | $32K | By Bios Fund III QP, LP | Nov 29, 2022 (1d) |
| Nov 28, 2022 | CGTX | ↑ Buy | 1,973 | $2.65 | $5K | By Bios Fund III NT, LP | Nov 29, 2022 (1d) |
| Nov 28, 2022 | CGTX | ↑ Buy | 1,871 | $2.65 | $5K | By Bios Fund III, LP | Nov 29, 2022 (1d) |
| Nov 16, 2022 | CGTX | ↑ Buy | 54,009 | $1.40 | $76K | By Bios Fund III QP, LP | Nov 17, 2022 (1d) |
| Nov 16, 2022 | CGTX | ↑ Buy | 8,722 | $1.40 | $12K | By Bios Fund III NT, LP | Nov 17, 2022 (1d) |
| Nov 16, 2022 | CGTX | ↑ Buy | 8,269 | $1.40 | $12K | Bios Fund III, LP | Nov 17, 2022 (1d) |
| Nov 15, 2022 | CGTX | ↑ Buy | 1,141,030 | $1.20 | $1.4M | By Bios Fund III QP, LP | Nov 16, 2022 (1d) |
| Nov 15, 2022 | CGTX | ↑ Buy | 184,270 | $1.20 | $221K | By Bios Fund III NT, LP | Nov 16, 2022 (1d) |
| Nov 15, 2022 | CGTX | ↑ Buy | 174,700 | $1.20 | $210K | Bios Fund III, LP | Nov 16, 2022 (1d) |
| Nov 8, 2022 | LTRN | ↓ Sell | 132,575 | $4.40 | $583K | By Bios Fund II QP, LP | Nov 9, 2022 (1d) |
| Nov 8, 2022 | LTRN | ↓ Sell | 100,380 | $4.40 | $442K | By Bios Fund I, LP | Nov 9, 2022 (1d) |
| Nov 8, 2022 | LTRN | ↓ Sell | 58,711 | $4.40 | $258K | By Bios Fund I QP, LP | Nov 9, 2022 (1d) |
| Nov 8, 2022 | LTRN | ↓ Sell | 40,586 | $4.40 | $179K | By Bios Fund II, LP | Nov 9, 2022 (1d) |
| Nov 8, 2022 | LTRN | ↓ Sell | 17,748 | $4.40 | $78K | By Bios Fund II NT, LP | Nov 9, 2022 (1d) |
| Sep 2, 2022 | LTRN | ↓ Sell | 6,445 | $5.20 | $34K | By BP Directors, LP | Sep 7, 2022 (5d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other ACTU insiders
Open-market trades in the last 12 months
About BIOS Fund I QP, LP's insider trades
BIOS Fund I QP, LP is a director at Actuate Therapeutics (ACTU). Since Sep 2, 2022, it has reported 15 open-market purchases worth $9.4M and 35 sales worth $3.9M on SEC Form 4. There have been no open-market trades in the last 12 months.
Its filings also include grants and awards (7 filings), option exercises (4 filings), conversions (3 filings), other transactions (2 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every ACTU insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.